Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

Lab: NCTR

104 Week

C10119 **NTP Study Number:**

06/02/2014 Lock Date:

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

ALL Removal Date Range:

Treatment Groups: Include 001 0 Vehicle 104 wk

Include 004 0.092 Furan104wk

Include 007 0.92 Furan 104wk

Include 002 0.02 Furan 104wk

Include 005 0.2 Furan 104 wk

Include 008 2 Furan 104 wk

Include 003 0.044 Furan104wk

Include 006 0.44 Furan 104wk

Study Gender: Male

TDMSE Version: 3.0.2.0_001

PWG Approval Date: NONE

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Disposition Summary						
Animals Initially In Study	150	150	100	100	50	50
Early Deaths						
Accidentally Killed				1		
Moribund Sacrifice	71	68	45	38	19	20
Natural Death	8	3	7	6	2	5
Survivors						
Moribund Sacrifice	24	30	17	25	12	11
Natural Death	2	7	3	2	1	1
Terminal Sacrifice	45	42	28	28	16	13
Animals Examined Microscopically	150	150	100	100	50	50
ALIMENTARY SYSTEM						
Esophagus	(150)	(150)	(100)	(100)	(50)	(50)
Bacterium				1 (1%)		
Hemorrhage				1 (1%)		
Inflammation, Suppurative				1 (1%)		
Necrosis				1 (1%)		
Perforation					2 (4%)	
Ulcer				1 (1%)		
Lumen, Dilatation	1 (1%)					
Periesophageal Tissue, Foreign Body						
Periesophageal Tissue, Hemorrhage				1 (1%)		
Periesophageal Tissue, Infiltration Cellular, Polymorphonuclear						
Periesophageal Tissue, Necrosis				1 (1%)		
Intestine Large, Cecum	(140)	(142)	(91)	(93)	(47)	(44)
Edema		1 (1%)				
Hemorrhage						
Inflammation, Suppurative		1 (1%)				
Ulcer		1 (1%)				
Lumen, Dilatation		1 (1%)				
Mucosa, Hyperplasia		1 (1%)	1 (1%)		1 (2%)	1 (2%)
Intestine Large, Colon	(143)	(146)	(94)	(95)	(49)	(44)

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

Experiment Number: 10119 - 01

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Edema	1 (1%)					
Inflammation, Chronic Active	,					
Necrosis	1 (1%)					
Ulcer						
Epithelium, Cyst		1 (1%)				
Mucosa, Hyperplasia		1 (1%)	1 (1%)		1 (2%)	
Serosa, Inflammation, Chronic Active				1 (1%)		
Intestine Large, Rectum	(143)	(146)	(94)	(95)	(49)	(45)
Anus, Inflammation, Chronic				1 (1%)		
Mucosa, Hyperplasia		1 (1%)			1 (2%)	1 (2%)
Intestine Small, Duodenum	(144)	(145)	(94)	(95)	(48)	(44)
Inflammation, Suppurative						1 (2%)
Inflammation, Chronic Active	1 (1%)	1 (1%)				
Necrosis						1 (2%)
Ulcer		1 (1%)				
Mucosa, Hyperplasia	8 (6%)	8 (6%)	3 (3%)	2 (2%)	4 (8%)	3 (7%)
Intestine Small, Ileum	(139)	(142)	(91)	(92)	(47)	(44)
Necrosis	1 (1%)					
Mucosa, Hyperplasia		1 (1%)	1 (1%)		1 (2%)	
Intestine Small, Jejunum	(140)	(142)	(91)	(93)	(47)	(44)
Edema	1 (1%)					
Infiltration Cellular, Polymorphonuclear	1 (1%)					
Inflammation, Chronic Active			1 (1%)			
Mucosa, Hyperplasia			2 (2%)		1 (2%)	
Serosa, Hemorrhage			1 (1%)			
Serosa, Necrosis			1 (1%)			
Liver	(149)	(150)	(99)	(100)	(50)	(49)
Angiectasis				1 (1%)		
Basophilic Focus	28 (19%)	16 (11%)	19 (19%)	18 (18%)	11 (22%)	13 (27%)
Cholangiofibrosis				1 (1%)	38 (76%)	49 (100%)
Clear Cell Focus	6 (4%)	4 (3%)	2 (2%)	1 (1%)	1 (2%)	
Congestion				1 (1%)		
Deformity	5 (3%)	4 (3%)	1 (1%)	2 (2%)	1 (2%)	
Degeneration, Cystic	25 (17%)	7 (5%)	11 (11%)	15 (15%)	8 (16%)	11 (22%)
Eosinophilic Focus	2 (1%)	1 (1%)	•	1 (1%)	1 (2%)	2 (4%)
Fibrosis	1 (1%)		1 (1%)	1 (1%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Species/Strain: RATS/F 344/NCTR

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42

First Dose M/F: 09/07/09 / NA

SCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104w
Granuloma	27 (18%)	27 (18%)	18 (18%)	20 (20%)	2 (4%)	7 (14%)
Hematopoietic Cell Proliferation	, ,	, ,	, ,	, ,	, ,	, ,
Hemorrhage		2 (1%)	2 (2%)			
Hepatodiaphragmatic Nodule	4 (3%)	3 (2%)	3 (3%)			1 (2%)
Hyperplasia, Regenerative		1 (1%)	1 (1%)	2 (2%)	1 (2%)	1 (2%)
Inflammation, Suppurative						2 (4%)
Inflammation, Chronic Active	5 (3%)	2 (1%)		1 (1%)		, ,
Mixed Cell Focus	7 (5%)	7 (5%)	6 (6%)	3 (3%)	5 (10%)	3 (6%)
Pigmentation	1 (1%)		1 (1%)			3 (6%)
Polyarteritis	1 (1%)					
Tension Lipidosis	3 (2%)	3 (2%)	4 (4%)	2 (2%)	1 (2%)	
Thrombosis	4 (3%)	2 (1%)	1 (1%)	, ,	, ,	
Vacuolization Cytoplasmic	23 (15%)	23 (15%)	14 (14%)	19 (19%)	12 (24%)	18 (37%)
Bile Duct, Biliary Tract, Cyst Multilocular	1 (1%)	,	,	,	, ,	,
Bile Duct, Biliary Tract, Hyperplasia	89 (60%)	86 (57%)	59 (60%)	56 (56%)	29 (58%)	25 (51%)
Bile Duct, Subcapsular, Hyperplasia	,	,	,	,	, ,	, ,
Capsule, Fibrosis		1 (1%)	1 (1%)	1 (1%)	1 (2%)	
Capsule, Infiltration Cellular, Polymorphonuclear	1 (1%)	, ,	, ,	, ,	, ,	
Capsule, Inflammation, Chronic Active		1 (1%)				
Capsule, Necrosis		1 (1%)				
Capsule, Pigmentation	1 (1%)					
Centrilobular, Hepatocyte, Degeneration	29 (19%)	25 (17%)	18 (18%)	16 (16%)	13 (26%)	11 (22%)
Centrilobular, Hepatocyte, Necrosis	1 (1%)	2 (1%)				1 (2%)
Hepatocyte, Hypertrophy			1 (1%)		1 (2%)	2 (4%)
Hepatocyte, Necrosis	12 (8%)	9 (6%)	8 (8%)	4 (4%)	6 (12%)	2 (4%)
Hepatocyte, Periportal, Degeneration					1 (2%)	
Oval Cell, Hyperplasia	14 (9%)	15 (10%)	10 (10%)	8 (8%)	7 (14%)	6 (12%)
Periportal, Cytoplasmic Alteration						1 (2%)
Periportal, Vacuolization Cytoplasmic	34 (23%)	27 (18%)	18 (18%)	12 (12%)	4 (8%)	7 (14%)
Subcapsular, Fibrosis	, ,	, ,	, ,	, ,	1 (2%)	, ,
Subcapsular, Inflammation, Chronic					1 (2%)	1 (2%)
Subcapsular, Pigmentation					1 (2%)	, ,
Mesentery	(31)	(35)	(25)	(25)	(14)	(8)
Accessory Spleen	1 (3%)	. ,	. ,	. ,	. ,	. ,
Cyst			1 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

Experiment Number: 10119 - 01

Furan CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Inflammation, Granulomatous			1 (4%)	1 (4%)		
Inflammation, Chronic Active		1 (3%)	` ,	, ,		
Mineralization		, ,				
Pigmentation		1 (3%)				
Fat, Hemorrhage	1 (3%)	1 (3%)		1 (4%)		
Fat, Necrosis	28 (90%)	31 (89%)	24 (96%)	23 (92%)	13 (93%)	7 (88%)
Oral Mucosa	(1)	(1)	(3)	(1)	(0)	(1)
Hemorrhage	, ,		1 (33%)	, ,		. ,
Inflammation, Chronic Active			,			1 (100%)
Epithelium, Hyperplasia			1 (33%)			,
Gingival, Ulcer			,			1 (100%)
Pancreas	(150)	(149)	(99)	(100)	(50)	(49)
Edema	,	1 (1%)	,	1 (1%)	,	,
Infiltration Cellular, Lymphocyte		,		,	1 (2%)	
Inflammation, Chronic Active	1 (1%)				,	
Necrosis	1 (1%)					
Pigmentation	,					1 (2%)
Polyarteritis	1 (1%)		3 (3%)	1 (1%)		1 (2%)
Acinar Cell, Hyperplasia	26 (17%)	16 (11%)	17 (17%)	17 (17%)	9 (18%)	7 (14%)
Acinus, Degeneration	32 (21%)	39 (26%)	21 (21%)	17 (17%)	17 (34%)	11 (22%)
Artery, Fibrosis	,	, ,	, ,	, ,	, ,	,
Artery, Hyperplasia	1 (1%)	1 (1%)				
Salivary Glands	(150)	(150)	(99)	(100)	(50)	(49)
Infiltration Cellular, Lymphocyte	, ,	, ,	1 (1%)	1 (1%)	, ,	. ,
Acinar Cell, Hyperplasia	1 (1%)		,	,		
Acinus, Degeneration	,		1 (1%)	1 (1%)		
Stomach, Forestomach	(149)	(150)	(99)	(100)	(50)	(49)
Edema	27 (18%)	22 (15%)	13 (13%)	16 (16%)	15 (30%)	12 (24%)
Fibrosis	1 (1%)	,	1 (1%)	, ,	1 (2%)	,
Hyperplasia, Basal Cell	1 (1%)		,		,	
Inflammation, Chronic Active	33 (22%)	31 (21%)	18 (18%)	19 (19%)	14 (28%)	15 (31%)
Necrosis	1 (1%)	1 (1%)	2 (2%)	,	,	, ,
Perforation	5 (3%)	5 (3%)	2 (2%)	4 (4%)	5 (10%)	2 (4%)
Ulcer	13 (9%)	17 (11%)	11 (11%)	7 (7%)	5 (10%)	9 (18%)
Epithelium, Hyperplasia	41 (28%)	41 (27%)	22 (22%)	24 (24%)	19 (38%)	17 (35%)
Serosa, Fibrosis	3 (2%)	4 (3%)	3 (3%)	1 (1%)	3 (6%)	` '

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Serosa, Inflammation, Suppurative		1 (1%)				
Serosa, Inflammation, Chronic Active	1 (1%)	, ,				
Serosa, Necrosis	, ,	1 (1%)				
Stomach, Glandular	(146)	(145)	(96)	(97)	(49)	(44)
Edema	1 (1%)	5 (3%)		2 (2%)	3 (6%)	1 (2%)
Inflammation, Chronic Active	3 (2%)	3 (2%)	2 (2%)	2 (2%)	3 (6%)	1 (2%)
Mineralization		1 (1%)	2 (2%)	1 (1%)		
Necrosis		1 (1%)	1 (1%)			1 (2%)
Ulcer	2 (1%)	1 (1%)			1 (2%)	2 (5%)
Mucosa, Hyperplasia	6 (4%)	12 (8%)	5 (5%)	5 (5%)	4 (8%)	3 (7%)
Tongue	(1)	(1)	(1)	(2)	(0)	(0)
Foreign Body			1 (100%)			
Inflammation, Chronic Active			1 (100%)			
Epithelium, Hyperplasia			1 (100%)	1 (50%)		
Blood Vessel Hemorrhage Inflammation, Chronic	(150)	(150) 1 (1%)	(100)	(100)	(49) 1 (2%)	(50)
Mineralization						
Heart	(150)	(150)	(100)	(100)	(50)	(50)
Cardiomyopathy	134 (89%)	138 (92%)	86 (86%)	89 (89%)	47 (94%)	46 (92%)
Congestion	1 (1%)	1 (1%)				
Foreign Body						
Hemorrhage		1 (1%)		1 (1%)		
Inflammation, Granulomatous						
Inflammation, Chronic Active				1 (1%)		
Metaplasia, Osseous	- (101)	- (101)	1 (1%)			. (221)
Mineralization	2 (1%)	2 (1%)	4 (4%)	1 (1%)	1 (2%)	1 (2%)
Pigmentation	00 (450)	1 (1%)	1 (1%)	40 (400()	0 (400()	7 (4.40()
Thrombosis	22 (15%)	20 (13%)	17 (17%)	12 (12%)	9 (18%)	7 (14%)
Atrium, Dilatation	1 (1%)		1 (1%)			
Myocardium, Necrosis	1 (1%)		4 (40()			
Pericardium, Fibrosis	1 (1%)		1 (1%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104v
Pericardium, Hemorrhage				1 (1%)		
Pericardium, Infiltration Cellular, Polymorphonuclear						
Pericardium, Inflammation, Suppurative				1 (1%)	1 (2%)	
Pericardium, Inflammation, Chronic Active				1 (1%)		
Pericardium, Necrosis				2 (2%)	1 (2%)	
Ventricle, Dilatation	2 (1%)		3 (3%)	1 (1%)		2 (4%)
ENDOCRINE SYSTEM						
Adrenal Cortex	(150)	(150)	(99)	(100)	(50)	(49)
Accessory Adrenal Cortical Nodule	4 (3%)	10 (7%)	2 (2%)	8 (8%)		1 (2%)
Angiectasis		1 (1%)				
Atrophy		1 (1%)				
Cyst	3 (2%)	1 (1%)	1 (1%)			1 (2%)
Fibrosis	1 (1%)	1 (1%)			1 (2%)	
Hyperplasia	10 (7%)	5 (3%)	5 (5%)	7 (7%)	1 (2%)	3 (6%)
Hypertrophy		1 (1%)	4 (4%)	1 (1%)		1 (2%)
Metaplasia, Osseous				1 (1%)		
Necrosis	2 (1%)	1 (1%)				
Pigmentation		1 (1%)				
Polyarteritis	1 (1%)					
Thrombosis	2 (1%)					
Vacuolization Cytoplasmic	121 (81%)	114 (76%)	69 (70%)	74 (74%)	45 (90%)	34 (69%)
Capsule, Fibrosis				1 (1%)	2 (4%)	
Adrenal Medulla	(150)	(150)	(99)	(100)	(50)	(49)
Fibrosis			1 (1%)		1 (2%)	
Hemorrhage	1 (1%)	1 (1%)			1 (2%)	
Hyperplasia	67 (45%)	74 (49%)	45 (45%)	35 (35%)	27 (54%)	18 (37%)
Mineralization	1 (1%)	1 (1%)	1 (1%)		1 (2%)	
Necrosis					1 (2%)	
Thrombosis	1 (1%)	2 (1%)	3 (3%)			
Islets, Pancreatic	(150)	(150)	(99)	(100)	(50)	(49)
Angiectasis			1 (1%)			
Hyperplasia	3 (2%)	8 (5%)	7 (7%)	3 (3%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

Pituitary Gland (150) (148) (100) (100) (50) Hemorrhage 3 (2%) 5 (3%) 4 (4%) 7 (7%) 4 (8%) Pigmentation 1 (1%) 1 (1%) 1 (1%) 1 (2%) Pars Distalis, Angiectasis 1 (1%) 1 (1%) 2 (2%) Pars Distalis, Cyst 12 (8%) 5 (3%) 4 (4%) 5 (5%) 3 (6%) Pars Distalis, Hyperplasia 27 (18%) 29 (20%) 28 (28%) 23 (23%) 7 (14%) 1 Pars Distalis, Necrosis 1 (1%) 1 (1%) 1 (2%) 1 1 (2%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) 1 (2%) 1 1 (2%) 1 1 (2%) 1 1 (2%) 1 (2%) 1 (2%) 1 (1%) 1 (2%)<	uran 104wk	0.44 Fura	0.2 Furan 104 wk	0.092 Furan104wk	0.044 Furan104wk	0.02 Furan 104wk	0 Vehicle 104 wk	FISCHER 344 RATS-NCTR RATS MALE
Angiectasis								Necrosis
Fibrosis Hyperplasia 38 (26%) 25 (17%) 11 (11%) 15 (15%) 8 (16%) 5 Pituitary Gland (150) (148) (100) (100) (50) Hemorrhage 3 (2%) 5 (3%) 4 (4%) 7 (7%) 4 (8%) 1 Pigmentation 1 (11%) 1 (1%) 1 (1%) 2 (2%) Pars Distalis, Angiectasis 1 (11%) 1 (1%) 1 (1%) 2 (2%) Pars Distalis, Cyst 12 (8%) 5 (3%) 4 (4%) 5 (5%) 3 (6%) 1 Pars Distalis, Cyst 12 (8%) 5 (3%) 4 (4%) 5 (5%) 3 (6%) 1 Pars Distalis, Hyerplasia 27 (18%) 29 (20%) 28 (28%) 23 (23%) 7 (14%) 1 Pars Distalis, Hyerplasia 1 (1%) 1 (1%) 1 (1%) 1 (1%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) Pars Intermedia, Hyperplasia Pars Nervosa, Cyst 1 (1%) 1 (1%) Pars Nervosa, Cyst 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 2 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 2 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1	(49)	(4	(50)	(98)	(98)	(150)	(149)	Parathyroid Gland
Hyperplasia 38 (26%) 25 (17%) 11 (11%) 15 (15%) 8 (16%) 5 (17%) 11 (11%) 15 (15%) 8 (16%) 5 (17%) 11 (11%) 15 (15%) 8 (16%) 5 (17%) 11 (11%) 15 (15%) 8 (16%) 5 (17%) 11 (11%) 15 (15%) 15							1 (1%)	Angiectasis
Pituitary Gland (150) (148) (100) (100) (50) Hemorrhage 3 (2%) 5 (3%) 4 (4%) 7 (7%) 4 (8%) Pigmentation 1 (1%) 1 (1%) 1 (1%) 1 (2%) Pars Distalis, Angiectasis 1 (1%) 1 (1%) 1 (1%) 2 (2%) Pars Distalis, Lycyt 12 (8%) 5 (3%) 4 (4%) 5 (5%) 3 (6%) 3 Pars Distalis, Necrosis 1 (1%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) Pars Intermedia, Cyst 1 (1%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (1%) 1 (1								Fibrosis
Hemorrhage 3 (2%) 5 (3%) 4 (4%) 7 (7%) 4 (8%) 7 (7%) 4 (8%) 7 (7%) 1 (2%) 7 (7%) 1 (2%) 7 (2%)	5 (10%)	5 (1	8 (16%)	15 (15%)	11 (11%)	25 (17%)	38 (26%)	Hyperplasia
Pigmentation 1 (1%) 1 (1%) 1 (1%) 1 (2%) Pars Distalis, Anglectasis 1 (1%) 1 (1%) 2 (2%) Pars Distalis, Cyst 12 (8%) 5 (3%) 4 (4%) 5 (5%) 3 (6%) Pars Distalis, Hyperplasia 27 (18%) 29 (20%) 28 (28%) 23 (23%) 7 (14%) 1 Pars Distalis, Necrosis 1 (1%) 1 (1%) 1 (2%) 1 Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) 1 (2%) Pars Intermedia, Hyperplasia 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (1%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%)	(49)	(4	(50)	(100)	(100)	(148)	(150)	Pituitary Gland
Pars Distalis, Angiectasis 1 (1%) 1 (1%) 2 (2%) Pars Distalis, Cyst 12 (8%) 5 (3%) 4 (4%) 5 (5%) 3 (6%) Pars Distalis, Hyperplasia 27 (18%) 29 (20%) 28 (28%) 23 (23%) 7 (14%) 1 Pars Distalis, Hyperplasia 1 (1%) 1 (1%) 1 (2%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) Pars Intermedia, Hyperplasia 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Cyst 1 (1%) 1 (1%) 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) 1 (1%) 1 (2%) Thyroid Gland (150) (150) (99) (100) (50) Cyst 1 (1%) 2 (52%) 29 (58%) 2 (52%) 29 (58%) 2 (52%) 2 (52%) 2 (52%)	3 (6%)	3 (6	4 (8%)	7 (7%)	4 (4%)	5 (3%)	3 (2%)	Hemorrhage
Pars Distalis, Cyst 12 (8%) 5 (3%) 4 (4%) 5 (5%) 3 (6%) 2 Pars Distalis, Hyperplasia 27 (18%) 29 (20%) 28 (28%) 23 (23%) 7 (14%) 1 Pars Distalis, Necrosis 1 (1%) 1 (1%) 1 (2%) 1 (2%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (1%) 1 (2%) Pars Intermedia, Hyperplasia 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (2%) 1 (2%) 1 (1%) 1 (2%) 1 (2%) 1 (1%) 1 (1%) 1 (2%) 1 (1%) 1 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)			1 (2%)			1 (1%)	1 (1%)	Pigmentation
Pars Distalis, Hyperplasia 27 (18%) 29 (20%) 28 (28%) 23 (23%) 7 (14%) 1 Pars Distalis, Necrosis 1 (1%) 1 (1%) 1 (2%) 1 1 1 (2%) 1 1 1 (2%) 1 1 1 (2%) 1 1 1 1 1 1 1 1 2%) 1 1 1 1 1 2%) 1 1 1 1 1 2%) 1 1 1 2%) 1 1 2%) 1 1 2%) 1 2%) 1 2%) 2 <td< td=""><td></td><td></td><td></td><td>2 (2%)</td><td>1 (1%)</td><td>1 (1%)</td><td>1 (1%)</td><td>Pars Distalis, Angiectasis</td></td<>				2 (2%)	1 (1%)	1 (1%)	1 (1%)	Pars Distalis, Angiectasis
Pars Distalis, Necrosis 1 (1%) 1 (1%) 1 (2%) Pars Intermedia, Cyst 3 (2%) 1 (1%) 1 (2%) Pars Intermedia, Hyperplasia 1 1 (1%) 1 (1%) Pars Nervosa, Cyst 1 (1%) 1 (2%) Pars Nervosa, Hyperplasia 1 (1%) 1 (2%) Rathke's Cleft, Cyst 1 (1%) 1 (2%) Thyroid Gland (150) (150) (99) (100) (50) Cyst 1 (1%) 2 (1%) 2 (1%) 2 (1%) 2 (1%) 3 (3%) 5 (10%) 5 (10%) 2 (1%) 3 (3%) 5 (10%) 5 (10%) 2 (1%) 1 (1	3 (6%)	3 (6	3 (6%)	5 (5%)	4 (4%)	5 (3%)	12 (8%)	Pars Distalis, Cyst
Pars Intermedia, Cyst 3 (2%) 1 (1%) Pars Intermedia, Hyperplasia Pars Nervosa, Cyst 1 (1%) Pars Nervosa, Hyperplasia 1 (1%) Rathke's Cleft, Cyst 1 (1%) 1 (2%) Thyroid Gland (150) (150) (99) (100) (50) Cyst 1 (1%) Ectopic Thymus 1 (1%) Fibrosis 1 (1%) Ultimobranchial Cyst 1 (1%) C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 2. Follicular Cell, Hyperplasia 2 (1%) 1 (1%) 1 (1%) GENERAL BODY SYSTEM Peritoneum (1) (5) (1) (0) (0) Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)	1 (22%)	11 (2	7 (14%)	23 (23%)	28 (28%)	29 (20%)	27 (18%)	Pars Distalis, Hyperplasia
Pars Intermedia, Hyperplasia Pars Nervosa, Cyst Pars Nervosa, Hyperplasia Rathke's Cleft, Cyst 1 (1%) 1 (2%) Thyroid Gland (150) (150) (99) (100) (50) Cyst Ectopic Thymus Fibrosis 1 (1%) Fibrosis 1 (1%) 1 (1%) C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 20 Follicle, Cyst Follicular Cell, Hyperplasia Pars Nervosa, Cyst 1 (1%) 1 (2%) 1 (10%) 1 (10%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) GENERAL BODY SYSTEM Peritoneum (1) Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)			1 (2%)	·	1 (1%)	1 (1%)		Pars Distalis, Necrosis
Pars Nervosa, Cyst Pars Nervosa, Hyperplasia Rathke's Cleft, Cyst 1 (1%) 1 (2%) Thyroid Gland Cyst Ectopic Thymus Fibrosis Ultimobranchial Cyst C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) Follicular Cell, Hyperplasia Peritoneum Peritoneum Pigmentation 1 (20%) Tissue NOS 1 (1%) 1					1 (1%)		3 (2%)	Pars Intermedia, Cyst
Pars Nervosa, Hyperplasia 1 (1%) 1 (2%) Rathke's Cleft, Cyst 1 (1%) 1 (2%) Thyroid Gland (150) (150) (99) (100) (50) Cyst 1 (1%) 2 (1%) 2 (1%) 3 (3%) 5 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 7 (10%) 7 (10%) <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>, ,</td> <td>-</td>							, ,	-
Pars Nervosa, Hyperplasia 1 (1%) 1 (2%) Rathke's Cleft, Cyst 1 (1%) 1 (2%) Thyroid Gland (150) (150) (99) (100) (50) Cyst 1 (1%) 2 (1%) 2 (1%) 3 (3%) 5 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 6 (10%) 7 (10%) 7 (10%) <td></td> <td></td> <td></td> <td>1 (1%)</td> <td></td> <td></td> <td></td> <td></td>				1 (1%)				
Rathke's Cleft, Cyst 1 (1%) 1 (2%) Thyroid Gland (150) (150) (99) (100) (50) Cyst 1 (1%) Ectopic Thymus 1 (1%) Fibrosis 1 (1%) 1 (1%) Ultimobranchial Cyst 1 (1%) C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 25 Follicle, Cyst 8 (5%) 6 (4%) 4 (4%) 3 (3%) 5 (10%) Follicular Cell, Hyperplasia 2 (1%) 1 (1%) 1 (1%) GENERAL BODY SYSTEM Peritoneum (1) (5) (1) (0) (0) Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)				, ,			1 (1%)	Pars Nervosa, Hyperplasia
Thyroid Gland (150) (150) (99) (100) (50) Cyst			1 (2%)					
Cyst 1 (1%) Ectopic Thymus 1 (1%) Fibrosis 1 (1%) Ultimobranchial Cyst 1 (1%) C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 20 Follicle, Cyst 8 (5%) 6 (4%) 4 (4%) 3 (3%) 5 (10%) Follicular Cell, Hyperplasia 2 (1%) 1 (1%) 1 (1%) GENERAL BODY SYSTEM Peritoneum (1) (5) (1) (0) (0) Pigmentation 1 (20%) 1 ((49)	(4		(100)	(99)	(150)	(150)	Thyroid Gland
Ectopic Thymus 1 (1%) Fibrosis 1 (1%) Ultimobranchial Cyst 1 (1%) C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 25 (50%) Follicle, Cyst 8 (5%) 6 (4%) 4 (4%) 3 (3%) 5 (10%) Follicular Cell, Hyperplasia 2 (1%) 1 (1%) 1 (1%) GENERAL BODY SYSTEM Peritoneum (1) (5) (1) (0) (0) Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)	. ,	,	, ,	1 (1%)	. ,	, ,	, ,	Cyst
Ultimobranchial Cyst C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 21 Follicle, Cyst Follicular Cell, Hyperplasia 6 (4%) 7 (1%) 6 (4%) 7 (1%) 7 (1%) 7 (1%) 7 (1%) 8 (5) 8 (5%) 8				, ,		1 (1%)		Ectopic Thymus
Ultimobranchial Cyst C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 21 Follicle, Cyst Follicular Cell, Hyperplasia 8 (5%) 6 (4%) 4 (4%) 3 (3%) 5 (10%) Follicular Cell, Hyperplasia CENERAL BODY SYSTEM Peritoneum Peritoneum 1 (20%) Tissue NOS (2) (1) (2) (2) (0)					1 (1%)	1 (1%)		Fibrosis
C-cell, Hyperplasia 95 (63%) 83 (55%) 53 (54%) 52 (52%) 29 (58%) 22 (50%) 50 (50%) 5						, ,		Ultimobranchial Cyst
Follicular Cell, Hyperplasia 8 (5%) 6 (4%) 4 (4%) 3 (3%) 5 (10%) Follicular Cell, Hyperplasia 2 (1%) 1 (1%) 1 (1%) GENERAL BODY SYSTEM Peritoneum (1) (5) (1) (0) (0) Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)	8 (57%)	28 (5	29 (58%)	52 (52%)		83 (55%)	95 (63%)	C-cell, Hyperplasia
Follicular Cell, Hyperplasia 2 (1%) 1 (1%) 1 (1%) GENERAL BODY SYSTEM Peritoneum (1) (5) (1) (0) (0) Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)	1 (2%)	1 (2	5 (10%)	3 (3%)	4 (4%)	6 (4%)	8 (5%)	
Peritoneum (1) (5) (1) (0) (0) Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)		·	, ,	1 (1%)	1 (1%)	2 (1%)		Follicular Cell, Hyperplasia
Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)								GENERAL BODY SYSTEM
Pigmentation 1 (20%) Tissue NOS (2) (1) (2) (2) (0)	(1)	1.	(0)	(0)	(1)	(5)	(1)	Peritoneum
Tissue NOS (2) (1) (2) (2) (0)	(')	()	(0)	(0)	(1)		(1)	
	(0)	(((0)	(2)	(2)		(2)	•
Homomago H (0070)	(0)	(0	(0)	(~)	(4)	(1)		
Inflammation, Suppurative 1 (50%)					1 (50%)		1 (3070)	_
Necrosis 1 (50%)					1 (3070)		1 (50%)	* *
Mediastinum, Bacterium							1 (0070)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Mediastinum, Foreign Body Mediastinum, Hemorrhage Mediastinum, Inflammation, Suppurative Mediastinum, Inflammation, Chronic Mediastinum, Necrosis						
GENITAL SYSTEM						
Ductus Deferens Epididymis Degeneration, Cystic Edema	(0) (149)	(1) (149)	(0) (98) 1 (1%)	(0) (100)	(0) (50)	(0) (50)
Exfoliated Germ Cell Fibrosis	39 (26%) 2 (1%)	42 (28%)	21 (21%) 3 (3%)	32 (32%)	16 (32%)	15 (30%) 2 (4%)
Hypospermia Epithelium, Degeneration Fat, Necrosis	78 (52%) 64 (43%) 1 (1%)	79 (53%) 64 (43%)	46 (47%) 37 (38%)	48 (48%) 33 (33%)	28 (56%) 25 (50%) 1 (2%)	32 (64%) 20 (40%)
Lumen, Dilatation Mesothelium, Hyperplasia	(450)	(450)	(00)	1 (1%)	(50)	(40)
Preputial Gland Abscess Edema	(150) 17 (11%)	(150) 18 (12%) 1 (1%)	(99) 7 (7%)	(100) 10 (10%)	(50) 7 (14%)	(49) 9 (18%)
Fibrosis Hyperkeratosis Infiltration Cellular, Lymphocyte	72 (48%) 3 (2%) 1 (1%)	73 (49%)	49 (49%)	46 (46%) 3 (3%)	24 (48%)	23 (47%)
Inflammation, Suppurative Inflammation, Chronic Active Necrosis Ulcer	61 (41%) 66 (44%) 3 (2%)	65 (43%) 62 (41%) 2 (1%)	38 (38%) 49 (49%) 1 (1%)	35 (35%) 45 (45%) 2 (2%) 1 (1%)	23 (46%) 21 (42%)	13 (27%) 30 (61%) 1 (2%)
Acinus, Degeneration Acinus, Hyperplasia Duct, Ectasia	5 (3%) 81 (54%)	1 (1%) 10 (7%) 78 (52%)	3 (3%) 49 (49%)	48 (48%)	6 (12%) 33 (66%)	22 (45%)
Epithelium, Hyperplasia Prostate Abscess	3 (2%) (149)	2 (1%) (150) 1 (1%)	(98)	1 (1%) (100)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Species/Strain: RATS/F 344/NCTR

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42

First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Atrophy	27 (18%)	29 (19%)	15 (15%)	14 (14%)	7 (14%)	12 (24%)
Degeneration, Cystic	5 (3%)	6 (4%)	2 (2%)	3 (3%)	2 (4%)	1 (2%)
Fibrosis	5 (3%)	8 (5%)	2 (2%)	2 (2%)	3 (6%)	4 (8%)
Infiltration Cellular, Lymphocyte	1 (1%)					
Inflammation, Suppurative	100 (67%)	108 (72%)	74 (76%)	70 (70%)	38 (76%)	35 (71%)
Inflammation, Chronic Active	21 (14%)	12 (8%)	9 (9%)	12 (12%)	7 (14%)	6 (12%)
Mineralization		1 (1%)	1 (1%)		, ,	
Pigmentation		1 (1%)				
Polyarteritis		, ,				
Epithelium, Hyperplasia	40 (27%)	39 (26%)	19 (19%)	29 (29%)	7 (14%)	12 (24%)
Seminal Vesicle	(143)	(146)	(96)	(98)	(50)	(46)
Atrophy	51 (36%)	52 (36%)	28 (29%)	31 (32%)	18 (36%)	20 (43%)
Edema	1 (1%)					
Fibrosis					1 (2%)	
Inflammation, Suppurative	2 (1%)	2 (1%)	1 (1%)			
Inflammation, Chronic Active				1 (1%)	1 (2%)	
Adventitia, Inflammation, Suppurative						1 (2%)
Epithelium, Hyperplasia		1 (1%)				
Lumen, Dilatation	10 (7%)	14 (10%)	4 (4%)	15 (15%)	11 (22%)	1 (2%)
Serosa, Inflammation, Chronic Active				1 (1%)		
Testes	(150)	(149)	(98)	(100)	(50)	(49)
Mineralization	1 (1%)			1 (1%)		
Polyarteritis	28 (19%)	35 (23%)	14 (14%)	23 (23%)	10 (20%)	9 (18%)
Interstitial Cell, Hyperplasia	71 (47%)	72 (48%)	49 (50%)	42 (42%)	21 (42%)	22 (45%)
Seminiferous Tubule, Degeneration	116 (77%)	106 (71%)	68 (69%)	76 (76%)	40 (80%)	39 (80%)
HEMATOPOIETIC SYSTEM						
Bone Marrow	(148)	(150)	(95)	(100)	(49)	(49)
Fibrosis	3 (2%)	1 (1%)		2 (2%)	1 (2%)	1 (2%)
Hyperplasia, Megakaryocyte						
Hypocellularity	1 (1%)			1 (1%)		
Myelostromal Proliferation		1 (1%)				
Myeloid Cell, Hyperplasia	36 (24%)	27 (18%)	18 (19%)	20 (20%)	7 (14%)	12 (24%)
Lymph Node	(59)	(69)	(35)	(38)	(23)	(20)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

SCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Hyperplasia, Lymphoid			1 (3%)			1 (5%)
Infiltration Cellular, Plasma Cell				1 (3%)		1 (5%)
Inflammation, Granulomatous						
Axillary, Hemorrhage	1 (2%)					
Axillary, Hyperplasia, Lymphoid			1 (3%)			
Axillary, Infiltration Cellular, Plasma Cell				1 (3%)		
Axillary, Necrosis						
Cervical, Hemorrhage	1 (2%)					
Cervical, Hyperplasia, Lymphoid	1 (2%)					
Cervical, Infiltration Cellular, Plasma Cell	1 (2%)			1 (3%)		
Deep Cervical, Necrosis						
Hepatic, Hyperplasia, Lymphoid	1 (2%)					1 (5%)
Hepatic, Infiltration Cellular, Plasma Cell						1 (5%)
Hepatic, Inflammation, Granulomatous	1 (2%)	1 (1%)				2 (10%)
Hepatic, Necrosis						
Hepatic, Sinus, Dilatation						
Inguinal, Hyperplasia, Lymphoid				1 (3%)		
Inguinal, Infiltration Cellular, Plasma Cell	1 (2%)					1 (5%)
Inguinal, Infiltration Cellular, Polymorphonuclear	1 (2%)					
Lumbar, Hemorrhage		1 (1%)				
Lumbar, Hyperplasia, Lymphoid	3 (5%)	1 (1%)	1 (3%)	2 (5%)		1 (5%)
Lumbar, Infiltration Cellular, Histiocyte		1 (1%)				
Lumbar, Infiltration Cellular, Plasma Cell	3 (5%)	9 (13%)	2 (6%)	3 (8%)	2 (9%)	1 (5%)
Lumbar, Infiltration Cellular, Polymorphonuclear				1 (3%)		
Lumbar, Necrosis				1 (3%)		
Lumbar, Pigmentation		1 (1%)		1 (3%)		
Lumbar, Sinus, Dilatation	7 (12%)	11 (16%)	2 (6%)	5 (13%)	2 (9%)	1 (5%)
Mediastinal, Congestion			1 (3%)			
Mediastinal, Erythrophagocytosis		1 (1%)				
Mediastinal, Hemorrhage		2 (3%)	1 (3%)	1 (3%)		
Mediastinal, Hyperplasia, Lymphoid	3 (5%)	2 (3%)	1 (3%)			
Mediastinal, Infiltration Cellular, Plasma Cell	4 (7%)		2 (6%)	2 (5%)	3 (13%)	1 (5%)
Mediastinal, Necrosis						
Mediastinal, Pigmentation		2 (3%)				

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

Experiment Number: 10119 - 01

Furan CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

SISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104v
Mediastinal, Sinus, Dilatation		4 (6%)	2 (6%)	3 (8%)	1 (4%)	
Pancreatic, Bacterium				1 (3%)		
Pancreatic, Hemorrhage	1 (2%)		1 (3%)			
Pancreatic, Hyperplasia, Lymphoid	5 (8%)	5 (7%)	4 (11%)	2 (5%)	1 (4%)	3 (15%)
Pancreatic, Infiltration Cellular, Histiocyte			1 (3%)			
Pancreatic, Infiltration Cellular, Plasma Cell	6 (10%)	4 (6%)	2 (6%)	4 (11%)	5 (22%)	4 (20%)
Pancreatic, Inflammation, Granulomatous	3 (5%)	3 (4%)	2 (6%)	2 (5%)	1 (4%)	
Pancreatic, Necrosis				1 (3%)		
Pancreatic, Pigmentation			1 (3%)		1 (4%)	
Pancreatic, Sinus, Dilatation		1 (1%)	1 (3%)			
Popliteal, Infiltration Cellular, Plasma Cell		1 (1%)				
Popliteal, Sinus, Dilatation		1 (1%)				
Renal, Hemorrhage	1 (2%)	1 (1%)			1 (4%)	
Renal, Hyperplasia, Lymphoid	4 (7%)	4 (6%)	1 (3%)	1 (3%)	1 (4%)	1 (5%)
Renal, Infiltration Cellular, Plasma Cell	4 (7%)	2 (3%)	3 (9%)	4 (11%)	3 (13%)	2 (10%)
Renal, Inflammation, Granulomatous		2 (3%)				
Renal, Necrosis						
Renal, Pigmentation	2 (3%)	1 (1%)				1 (5%)
Renal, Sinus, Dilatation	4 (7%)	5 (7%)	6 (17%)	6 (16%)	2 (9%)	2 (10%)
Lymph Node, Mandibular	(150)	(150)	(99)	(100)	(50)	(49)
Hemorrhage	7 (5%)	3 (2%)	1 (1%)	3 (3%)		2 (4%)
Hyperplasia, Lymphoid	38 (25%)	31 (21%)	25 (25%)	21 (21%)	9 (18%)	12 (24%)
Infiltration Cellular, Plasma Cell	75 (50%)	73 (49%)	50 (51%)	48 (48%)	23 (46%)	17 (35%)
Necrosis				1 (1%)		
Pigmentation		2 (1%)				
Sinus, Dilatation	34 (23%)	41 (27%)	27 (27%)	22 (22%)	17 (34%)	12 (24%)
Lymph Node, Mesenteric	(147)	(146)	(93)	(97)	(49)	(47)
Hemorrhage	2 (1%)	2 (1%)	1 (1%)	2 (2%)		
Hyperplasia, Lymphoid	42 (29%)	41 (28%)	29 (31%)	23 (24%)	12 (24%)	16 (34%)
Infiltration Cellular, Histiocyte		•	·	•	1 (2%)	• •
Infiltration Cellular, Mast Cell	1 (1%)					
Infiltration Cellular, Plasma Cell	13 (9%)	11 (8%)	2 (2%)	16 (16%)	4 (8%)	4 (9%)
Inflammation, Granulomatous	4 (3%)	1 (1%)	1 (1%)	3 (3%)	1 (2%)	. ,
Pigmentation	1 (1%)	1 (1%)	1 (1%)	1 (1%)	. ,	
Sinus, Dilatation	2 (1%)	1 (1%)	2 (2%)	1 (1%)	1 (2%)	
Spleen	(150)	(149)	(98)	(100)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104v
Accessory Spleen			1 (1%)			
Atrophy			` ,			1 (2%)
Cyst	1 (1%)					
Developmental Malformation	1 (1%)		1 (1%)	1 (1%)		
Fibrosis	7 (5%)	12 (8%)	11 (11%)	15 (15%)	5 (10%)	5 (10%)
Hematopoietic Cell Proliferation	52 (35%)	46 (31%)	35 (36%)	36 (36%)	16 (32%)	13 (27%)
Hemorrhage		1 (1%)			1 (2%)	
Hyperplasia, Lymphoid	5 (3%)	6 (4%)	1 (1%)	3 (3%)	1 (2%)	
Hyperplasia, Stromal	, ,	1 (1%)	` ,	, ,	, ,	
Necrosis	3 (2%)	2 (1%)	2 (2%)	3 (3%)	4 (8%)	1 (2%)
Pigmentation	67 (45%)	64 (43%)	43 (44%)	37 (37%)	14 (28%)	18 (37%)
Thrombosis	,	,	,	,	,	, ,
Capsule, Fibrosis	2 (1%)	2 (1%)	2 (2%)		2 (4%)	
Thymus	(144)	(149)	(98)	(98)	(49)	(48)
Atrophy	136 (94%)	142 (95%)	93 (95%)	91 (93%)	47 (96%)	45 (94%)
Cyst	,	,	,	1 (1%)	,	,
Hemorrhage	1 (1%)			,		
Hyperplasia, Lymphoid	,					
Necrosis				2 (2%)	1 (2%)	
Adventitia, Foreign Body				1 (1%)	,	
Adventitia, Infiltration Cellular, Polymorphonuclear				2 (2%)	1 (2%)	
Epithelium, Hyperplasia						
NTEGUMENTARY SYSTEM						
Mammary Gland	(150)	(148)	(95)	(100)	(50)	(50)
Abscess						1 (2%)
Fibrosis				1 (1%)		
Galactocele	75 (50%)	72 (49%)	46 (48%)	45 (45%)	23 (46%)	21 (42%)
Hemorrhage	1 (1%)	1 (1%)			1 (2%)	
Inflammation, Granulomatous	1 (1%)		1 (1%)	1 (1%)		2 (4%)
Inflammation, Chronic				2 (2%)	1 (2%)	
Inflammation, Chronic Active	1 (1%)	1 (1%)	1 (1%)	1 (1%)	1 (2%)	
Pigmentation	1 (1%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Alveolus, Dilatation	33 (22%)	28 (19%)	15 (16%)	19 (19%)	14 (28%)	10 (20%)
Epithelium, Hyperplasia	9 (6%)	10 (7%)	6 (6%)	9 (9%)	4 (8%)	3 (6%)
Lobular, Hyperplasia	13 (9%)	17 (11%)	13 (14%)	15 (15%)	7 (14%)	4 (8%)
Skin	(150)	(150)	(100)	(99)	(50)	(50)
Abscess	2 (1%)	2 (1%)	1 (1%)		1 (2%)	2 (4%)
Cyst Epithelial Inclusion	4 (3%)	5 (3%)	5 (5%)	1 (1%)	5 (10%)	3 (6%)
Fibrosis	3 (2%)	2 (1%)	1 (1%)	2 (2%)	1 (2%)	, ,
Foreign Body	, ,	, ,	` ,	, ,	, ,	1 (2%)
Hyperkeratosis	1 (1%)	2 (1%)				, ,
Inflammation, Granulomatous	, ,	, ,	1 (1%)			
Inflammation, Chronic Active			,	1 (1%)		
Metaplasia, Osseous				, ,		
Ulcer						
Ear, Fibrosis						1 (2%)
Ear, Epithelium, Hyperplasia					1 (2%)	1 (2%)
Ear, Sebaceous Gland, Hyperplasia					1 (2%)	,
Epithelium, Hyperplasia	1 (1%)	1 (1%)	1 (1%)		,	
Tail, Cyst Epithelial Inclusion	, ,	, ,	2 (2%)			
MUSCULOSKELETAL SYSTEM		_				
Bone	(5)	(1)	(0)	(0)	(1)	(0)
Rib, Cyst	1 (20%)					
Tibia, Deformity	1 (20%)					
Bone, Femur	(150)	(150)	(100)	(100)	(50)	(50)
Fibrosis	, ,	, ,	, ,	1 (1%)	, ,	` ,
Fibrous Osteodystrophy	1 (1%)	1 (1%)	4 (4%)	2 (2%)	1 (2%)	
Osteopetrosis	, ,	, ,	1 (1%)	1 (1%)	, ,	
Skeletal Muscle	(7)	(4)	(2)	(1)	(1)	(1)
Fibrosis	1 (14%)	. ,	()	,	()	,
Necrosis	,		1 (50%)			
Diaphragm, Hemorrhage			(/			
Diaphragm, Infiltration Cellular, Polymorphonuclear						
Diaphragm, Necrosis						

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104w
NERVOUS SYSTEM						
Brain	(0)	(0)	(0)	(0)	(0)	(0)
Meninges, Mineralization	(0)	(0)	(0)	(0)	(0)	(0)
Brain, Brain Stem	(150)	(150)	(00)	(100)	(EO)	(50)
•	, ,	, ,	(99)	, ,	(50)	(50)
Compression	59 (39%)	62 (41%)	40 (40%)	42 (42%)	20 (40%)	21 (42%)
Hemorrhage	4 (3%)	7 (5%)	2 (2%)	2 (2%)	3 (6%)	4 (8%)
Necrosis	2 (1%)	1 (1%)	(00)	(400)	(50)	1 (2%)
Brain, Cerebellum	(150)	(149)	(99)	(100)	(50)	(50)
Gliosis	4 (40()	1 (1%)	0 (00()	0 (00()		4 (00()
Hemorrhage	1 (1%)	5 (3%)	2 (2%)	2 (2%)		1 (2%)
Metaplasia, Osseous	4 (40()		1 (1%)			
Mineralization	1 (1%)	- ()			. (221)	
Necrosis	1 (1%)	2 (1%)	1 (1%)		1 (2%)	
Ventricle, Dilatation	2 (1%)	1 (1%)	1 (1%)			
Brain, Cerebrum	(150)	(150)	(99)	(100)	(50)	(50)
Compression						
Cyst	1 (1%)					
Gliosis	2 (1%)	1 (1%)			1 (2%)	
Hemorrhage	3 (2%)	4 (3%)	3 (3%)	1 (1%)	1 (2%)	3 (6%)
Mineralization	1 (1%)	2 (1%)	1 (1%)		1 (2%)	
Necrosis	2 (1%)	1 (1%)			1 (2%)	
Ventricle, Dilatation	18 (12%)	15 (10%)	11 (11%)	13 (13%)	5 (10%)	6 (12%)
Peripheral Nerve	(1)	(1)	(1)	(1)	(0)	(0)
Spinal Cord, Cervical	(1)	(1)	(1)	(1)	(0)	(0)
Hemorrhage				1 (100%)		
Axon, Degeneration				1 (100%)		
Spinal Cord, Lumbar	(1)	(1)	(1)	(1)	(0)	(0)
Axon, Degeneration		·		1 (100%)		
Spinal Cord, Thoracic	(1)	(1)	(1)	(1)	(0)	(0)
Hemorrhage	, ,	. ,	. ,	1 (100%)	. ,	. ,
Axon, Degeneration				1 (100%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
RESPIRATORY SYSTEM						
Lung	(150)	(149)	(99)	(100)	(50)	(50)
Bacterium				1 (1%)		
Congestion		1 (1%)		2 (2%)		
Crystals	1 (1%)				1 (2%)	
Fibrosis				1 (1%)		
Hemorrhage	4 (3%)	3 (2%)	3 (3%)	2 (2%)	1 (2%)	1 (2%)
Histiocytosis	1 (1%)			1 (1%)		
Infiltration Cellular, Histiocyte	35 (23%)	29 (19%)	16 (16%)	18 (18%)	13 (26%)	13 (26%)
Inflammation, Suppurative	2 (1%)	2 (1%)		2 (2%)		
Inflammation, Chronic	1 (1%)	1 (1%)		2 (2%)		
Inflammation, Chronic Active	2 (1%)	1 (1%)	1 (1%)	1 (1%)		
Metaplasia, Osseous	3 (2%)	,	,	,		
Mineralization	,					
Necrosis	1 (1%)	2 (1%)	1 (1%)	1 (1%)		
Pigmentation	1 (1%)	3 (2%)	,	,		
Polyarteritis	1 (1%)	1 (1%)		1 (1%)		
Thrombosis	,	,		,	1 (2%)	
Alveolar Epithelium, Hyperplasia	3 (2%)	2 (1%)	2 (2%)	1 (1%)	(/	2 (4%)
Bronchiole, Epithelium, Hyperplasia	- (7	()	1 (1%)	(/		(/
Mediastinum, Fibrosis			((, , , ,		1 (2%)	
Mediastinum, Hemorrhage					. (=,,,	
Mediastinum, Inflammation, Suppurative					3 (6%)	
Mediastinum, Inflammation, Chronic Active	1 (1%)				0 (070)	
Mediastinum, Necrosis	1 (170)			1 (1%)	3 (6%)	
Pleura, Bacterium				1 (1%)	1 (2%)	
Pleura, Foreign Body				1 (1%)	1 (2%)	
Pleura, Hemorrhage				1 (1%)	1 (2%)	
Pleura, Infiltration Cellular, Polymorphonuclear				1 (1%)	1 (270)	
Pleura, Inflammation, Suppurative				1 (1%)	1 (2%)	
Pleura, Inflammation, Chronic				1 (1%)	· (2/0)	
Pleura, Necrosis				2 (2%)	1 (2%)	
Nose	(149)	(146)	(96)	(97)	(48)	(48)
Cyst	(170)	(170)	(30)	(31)	(+0)	(40)
Foreign Body	11 (7%)	16 (11%)	9 (9%)	6 (6%)	5 (10%)	5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wk
Inflammation, Suppurative	19 (13%)	26 (18%)	18 (19%)	12 (12%)	10 (21%)	7 (15%)
Necrosis				1 (1%)		
Osteopetrosis			1 (1%)	1 (1%)		
Goblet Cell, Hyperplasia	3 (2%)	2 (1%)	1 (1%)			
Trachea	(150)	(150)	(99)	(100)	(50)	(50)
Inflammation, Suppurative		1 (1%)		1 (1%)		1 (2%)
Necrosis				1 (1%)		
Epithelium, Erosion						1 (2%)
SPECIAL SENSES SYSTEM						
Ear	(1)	(0)	(3)	(0)	(1)	(0)
Eye	(144)	(143)	(92)	(96)	(48)	(45)
Cataract	1 (1%)	2 (1%)	3 (3%)	4 (4%)	2 (4%)	4 (9%)
Hemorrhage						
Inflammation, Suppurative		1 (1%)				
Metaplasia, Osseous				1 (1%)		
Retinal Detachment				1 (1%)		
Adventitia, Inflammation, Suppurative			1 (1%)			
Cornea, Inflammation, Suppurative	1 (1%)					
Cornea, Ulcer	1 (1%)					
Optic Nerve, Degeneration						
Retina, Degeneration	10 (7%)	7 (5%)	4 (4%)	8 (8%)	4 (8%)	5 (11%)
Harderian Gland	(150)	(150)	(99)	(100)	(50)	(49)
Foreign Body			1 (1%)			
Infiltration Cellular, Lymphocyte	6 (4%)	6 (4%)	2 (2%)	5 (5%)	1 (2%)	1 (2%)
Inflammation, Suppurative		1 (1%)	1 (1%)			
Inflammation, Chronic Active					1 (2%)	
Polyarteritis	1 (1%)					
Acinus, Degeneration	1 (1%)	6 (4%)	3 (3%)	2 (2%)	1 (2%)	
Acinus, Hyperplasia	1 (1%)			1 (1%)		
Epithelium, Hyperplasia	1 (1%)	1 (1%)				
Zymbal's Gland	(6)	(3)	(2)	(3)	(0)	(1)
Abscess	1 (17%)					
Inflammation, Suppurative	2 (33%)	1 (33%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0 Vehicle 104 wk	0.02 Furan 104wk	0.044 Furan104wk	0.092 Furan104wk	0.2 Furan 104 wk	0.44 Furan 104wl
Keratin Cyst	1 (17%)					
JRINARY SYSTEM						
Kidney	(150)	(150)	(99)	(100)	(50)	(49)
Casts Protein	1 (1%)					
Cyst	4 (3%)	7 (5%)	1 (1%)	1 (1%)	2 (4%)	2 (4%)
Hydronephrosis	12 (8%)	15 (10%)	8 (8%)	10 (10%)	8 (16%)	5 (10%)
Infarct		1 (1%)				
Inflammation, Suppurative						1 (2%)
Mineralization						
Necrosis	1 (1%)	1 (1%)				
Nephropathy	148 (99%)	147 (98%)	98 (99%)	99 (99%)	49 (98%)	49 (100%)
Pigmentation	3 (2%)	2 (1%)		2 (2%)		1 (2%)
Polyarteritis		1 (1%)				
Polycystic Kidney			1 (1%)			
Thrombosis						
Capsule, Fibrosis		1 (1%)				
Pelvis, Inflammation, Suppurative	1 (1%)	3 (2%)		1 (1%)	1 (2%)	2 (4%)
Renal Tubule, Degeneration		3 (2%)				
Renal Tubule, Dilatation		1 (1%)				
Transitional Epithelium, Hyperplasia	27 (18%)	39 (26%)	25 (25%)	23 (23%)	14 (28%)	9 (18%)
Urethra	(0)	(2)	(0)	(1)	(0)	(0)
Bulbourethral Gland, Inflammation, Suppurative	. ,	1 (50%)	, ,	, ,	, ,	, ,
Lumen, Dilatation		1 (50%)				
Urinary Bladder	(150)	(150)	(99)	(100)	(50)	(48)
Hemorrhage		1 (1%)	1 (1%)		. ,	, ,
Inflammation, Suppurative		1 (1%)				
Inflammation, Chronic				1 (1%)		
Inflammation, Chronic Active		2 (1%)			1 (2%)	
Lumen, Dilatation	11 (7%)	14 (9%)	3 (3%)	10 (10%)	3 (6%)	4 (8%)
Serosa, Inflammation, Chronic Active	• •	, ,	. ,	1 (1%)	1 (2%)	` ,
Transitional Epithelium, Hyperplasia	2 (1%)	8 (5%)	4 (4%)	3 (3%)	1 (2%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

0.92 Furan 104wk	2 Furan 104 wk
50	50
อบ	50
20	22
29	22 5
	ບ
٥	15
3	13
12	8
	50
JU	30
(50)	(50)
(/	(/
	1 (2%)
	1 (2%)
	1 (2%)
(50)	(46)
` '	` '
	1 (2%)
	· · · /
	1 (2%)
(50)	(46)
	9 12 50 (50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Species/Strain: RATS/F 344/NCTR

Route: GAVAGE

Fibrosis

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Edema		
Inflammation, Chronic Active	1 (2%)	
Necrosis	(/	
Ulcer	1 (2%)	
Epithelium, Cyst	, ,	1 (2%)
Mucosa, Hyperplasia		2 (4%)
Serosa, Inflammation, Chronic Active		
Intestine Large, Rectum	(50)	(48)
Anus, Inflammation, Chronic		
Mucosa, Hyperplasia		2 (4%)
Intestine Small, Duodenum	(50)	(47)
Inflammation, Suppurative		
Inflammation, Chronic Active		
Necrosis		
Ulcer		
Mucosa, Hyperplasia		4 (9%)
Intestine Small, Ileum	(49)	(46)
Necrosis		
Mucosa, Hyperplasia		2 (4%)
Intestine Small, Jejunum	(50)	(46)
Edema		
Infiltration Cellular, Polymorphonuclear		
Inflammation, Chronic Active		
Mucosa, Hyperplasia		
Serosa, Hemorrhage		
Serosa, Necrosis	(50)	(40)
Liver	(50)	(49)
Angiectasis	1 (2%)	1 (2%)
Basophilic Focus	10 (20%)	21 (43%)
Cholangiofibrosis	47 (94%)	49 (100%)
Clear Cell Focus	7 (14%)	6 (12%)
Congestion	4 (00/)	1 (2%)
Deformity Degraporation Custing	1 (2%)	1 (2%)
Degeneration, Cystic	10 (20%)	17 (35%)
Eosinophilic Focus	2 (4%)	7 (14%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Granuloma	11 (22%)	8 (16%)
Hematopoietic Cell Proliferation	1 (2%)	c (1070)
Hemorrhage	2 (4%)	1 (2%)
Hepatodiaphragmatic Nodule	(/	2 (4%)
Hyperplasia, Regenerative	7 (14%)	12 (24%)
Inflammation, Suppurative	,	,
Inflammation, Chronic Active		1 (2%)
Mixed Cell Focus	6 (12%)	13 (27%)
Pigmentation	,	1 (2%)
Polyarteritis		,
Tension Lipidosis	1 (2%)	
Thrombosis	3 (6%)	1 (2%)
Vacuolization Cytoplasmic	23 (46%)	37 (76%)
Bile Duct, Biliary Tract, Cyst Multilocular	, ,	, ,
Bile Duct, Biliary Tract, Hyperplasia	32 (64%)	43 (88%)
Bile Duct, Subcapsular, Hyperplasia	1 (2%)	, ,
Capsule, Fibrosis	, ,	
Capsule, Infiltration Cellular, Polymorphonuclear		
Capsule, Inflammation, Chronic Active		
Capsule, Necrosis		
Capsule, Pigmentation		
Centrilobular, Hepatocyte, Degeneration	20 (40%)	19 (39%)
Centrilobular, Hepatocyte, Necrosis		
Hepatocyte, Hypertrophy	2 (4%)	5 (10%)
Hepatocyte, Necrosis	5 (10%)	4 (8%)
Hepatocyte, Periportal, Degeneration		
Oval Cell, Hyperplasia	14 (28%)	33 (67%)
Periportal, Cytoplasmic Alteration	3 (6%)	
Periportal, Vacuolization Cytoplasmic	3 (6%)	3 (6%)
Subcapsular, Fibrosis	1 (2%)	
Subcapsular, Inflammation, Chronic	1 (2%)	
Subcapsular, Pigmentation	1 (2%)	
Mesentery	(14)	(10)
Accessory Spleen	. ,	
Cyst		

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

Time Report Requested: 08:42:42

First Dose M/F: 09/07/09 / NA

Date Report Requested: 06/03/2014

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

CAS Number: 110-00-9

	2025 4511	
FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Inflammation, Granulomatous		
Inflammation, Chronic Active		
Mineralization	1 (7%)	
Pigmentation	. (,	
Fat, Hemorrhage		
Fat, Necrosis	11 (79%)	9 (90%)
Oral Mucosa	(0)	(0)
Hemorrhage	(-)	(-)
Inflammation, Chronic Active		
Epithelium, Hyperplasia		
Gingival, Ulcer		
Pancreas	(50)	(50)
Edema	()	()
Infiltration Cellular, Lymphocyte	1 (2%)	
Inflammation, Chronic Active	(=,2)	
Necrosis		1 (2%)
Pigmentation		(7
Polyarteritis	1 (2%)	
Acinar Cell, Hyperplasia	7 (14%)	8 (16%)
Acinus, Degeneration	14 (28%)	7 (14%)
Artery, Fibrosis	1 (2%)	` ,
Artery, Hyperplasia	, ,	
Salivary Glands	(50)	(50)
Infiltration Cellular, Lymphocyte	, ,	, ,
Acinar Cell, Hyperplasia		
Acinus, Degeneration	1 (2%)	
Stomach, Forestomach	(50)	(48)
Edema	9 (18%)	15 (31%)
Fibrosis	- (/	ζ/
Hyperplasia, Basal Cell		1 (2%)
Inflammation, Chronic Active	13 (26%)	19 (40%)
Necrosis	1 (2%)	- (/
Perforation	2 (4%)	3 (6%)
Ulcer	5 (10%)	9 (19%)
Epithelium, Hyperplasia	15 (30%)	21 (44%)
Serosa, Fibrosis	- ()	2 (4%)
		= (· · · · /

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Serosa, Inflammation, Suppurative		
Serosa, Inflammation, Chronic Active		
Serosa, Necrosis		1 (2%)
Stomach, Glandular	(50)	(48)
Edema	1 (2%)	1 (2%)
Inflammation, Chronic Active	1 (2%)	1 (2%)
Mineralization	1 (2%)	1 (2%)
Necrosis	. (=/0)	1 (2%)
Ulcer		. (=/0)
Mucosa, Hyperplasia	1 (2%)	5 (10%)
Tongue	(0)	(0)
Foreign Body	(~)	(-)
Inflammation, Chronic Active		
Epithelium, Hyperplasia		
. , , , , , ,		
OARRIOMACONII AR OVOTEM		
CARDIOVASCULAR SYSTEM		
Blood Vessel	(50)	(50)
Hemorrhage		
Inflammation, Chronic		
Mineralization	1 (2%)	
Heart	(50)	(50)
Cardiomyopathy	45 (90%)	44 (88%)
Congestion		. ,
Foreign Body	1 (2%)	
Hemorrhage	,	
Inflammation, Granulomatous	1 (2%)	
Inflammation, Chronic Active	(/	
Metaplasia, Osseous		
Mineralization	2 (4%)	1 (2%)
Pigmentation	_ (· , • ,	. (=/-//
Thrombosis	13 (26%)	3 (6%)
Atrium, Dilatation	10 (2070)	0 (070)
Myocardium, Necrosis		
Pericardium, Fibrosis		
i Gilcaiululli, Fibiosis		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Pericardium, Hemorrhage	1 (2%)	
Pericardium, Infiltration Cellular, Polymorphonuclear	1 (2%)	
Pericardium, Inflammation, Suppurative		
Pericardium, Inflammation, Chronic Active	1 (2%)	
Pericardium, Necrosis	1 (2%)	
Ventricle, Dilatation		
ENDOCRINE SYSTEM		
Adrenal Cortex	(50)	(50)
Accessory Adrenal Cortical Nodule	1 (2%)	2 (4%)
Angiectasis	, ,	1 (2%)
Atrophy		
Cyst		
Fibrosis		
Hyperplasia		
Hypertrophy	2 (4%)	1 (2%)
Metaplasia, Osseous	1 (2%)	
Necrosis		1 (2%)
Pigmentation		
Polyarteritis		
Thrombosis		
Vacuolization Cytoplasmic	35 (70%)	40 (80%)
Capsule, Fibrosis		1 (2%)
Adrenal Medulla	(50)	(50)
Fibrosis		
Hemorrhage		
Hyperplasia	19 (38%)	21 (42%)
Mineralization		
Necrosis		
Thrombosis		
Islets, Pancreatic	(50)	(50)
Angiectasis		
Hyperplasia	1 (2%)	3 (6%)
••	, ,	* *

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Necrosis		1 (2%)
Parathyroid Gland	(50)	(50)
Angiectasis	(65)	(00)
Fibrosis	1 (2%)	
Hyperplasia	7 (14%)	19 (38%)
Pituitary Gland	(50)	(50)
Hemorrhage	` ,	3 (6%)
Pigmentation		, ,
Pars Distalis, Angiectasis		
Pars Distalis, Cyst	4 (8%)	1 (2%)
Pars Distalis, Hyperplasia	12 (24%)	12 (24%)
Pars Distalis, Necrosis		
Pars Intermedia, Cyst		
Pars Intermedia, Hyperplasia	1 (2%)	
Pars Nervosa, Cyst		
Pars Nervosa, Hyperplasia		
Rathke's Cleft, Cyst		
Thyroid Gland	(50)	(50)
Cyst		
Ectopic Thymus		
Fibrosis		
Ultimobranchial Cyst		
C-cell, Hyperplasia	27 (54%)	28 (56%)
Follicle, Cyst	3 (6%)	7 (14%)
Follicular Cell, Hyperplasia		2 (4%)
GENERAL BODY SYSTEM		
Peritoneum	(1)	(1)
Pigmentation		
Tissue NOS	(3)	(0)
Hemorrhage		
Inflammation, Suppurative		
Necrosis	1 (33%)	
Mediastinum, Bacterium	1 (33%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Mediastinum, Foreign Body	1 (33%)	
Mediastinum, Hemorrhage	2 (67%)	
Mediastinum, Inflammation, Suppurative	1 (33%)	
Mediastinum, Inflammation, Chronic	1 (33%)	
Mediastinum, Necrosis	2 (67%)	
GENITAL SYSTEM		
Ductus Deferens	(0)	(0)
Epididymis	(50)	(50)
Degeneration, Cystic	()	()
Edema		1 (2%)
Exfoliated Germ Cell	18 (36%)	14 (28%)
Fibrosis	,	,
Hypospermia	27 (54%)	26 (52%)
Epithelium, Degeneration	25 (50%)	26 (52%)
Fat, Necrosis		
Lumen, Dilatation		
Mesothelium, Hyperplasia	1 (2%)	1 (2%)
Preputial Gland	(50)	(50)
Abscess	2 (4%)	6 (12%)
Edema		
Fibrosis	24 (48%)	21 (42%)
Hyperkeratosis	1 (2%)	
Infiltration Cellular, Lymphocyte		
Inflammation, Suppurative	24 (48%)	24 (48%)
Inflammation, Chronic Active	19 (38%)	18 (36%)
Necrosis		1 (2%)
Ulcer		
Acinus, Degeneration		
Acinus, Hyperplasia	1 (2%)	1 (2%)
Duct, Ectasia	28 (56%)	29 (58%)
Epithelium, Hyperplasia		
Prostate	(50)	(50)
Abscess		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Atrophy	7 (14%)	10 (20%)
Degeneration, Cystic	4 (8%)	1 (2%)
Fibrosis	2 (4%)	1 (2%)
Infiltration Cellular, Lymphocyte	- (. , 0)	. (= /0)
Inflammation, Suppurative	33 (66%)	36 (72%)
Inflammation, Chronic Active	5 (10%)	3 (6%)
Mineralization	3 (1.07.0)	0 (0,0)
Pigmentation		
Polyarteritis		1 (2%)
Epithelium, Hyperplasia	8 (16%)	14 (28%)
Seminal Vesicle	(50)	(48)
Atrophy	18 (36%)	17 (35%)
Edema	. 5 (5575)	(55,5)
Fibrosis		
Inflammation, Suppurative		
Inflammation, Chronic Active		
Adventitia, Inflammation, Suppurative		
Epithelium, Hyperplasia		
Lumen, Dilatation	3 (6%)	5 (10%)
Serosa, Inflammation, Chronic Active	- (- · - /	- (,
Testes	(50)	(50)
Mineralization	(/	3 (6%)
Polyarteritis	8 (16%)	12 (24%)
Interstitial Cell, Hyperplasia	28 (56%)	26 (52%)
Seminiferous Tubule, Degeneration	33 (66%)	37 (74%)
HEMATOPOIETIC SYSTEM	· ·	
HEINIATOPOIETIC STSTEIN		
Bone Marrow	(50)	(49)
Fibrosis		
Hyperplasia, Megakaryocyte		1 (2%)
Hypocellularity		
Myelostromal Proliferation		
Myeloid Cell, Hyperplasia	15 (30%)	21 (43%)
Lymph Node	(26)	(33)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Hyperplasia, Lymphoid		
Infiltration Cellular, Plasma Cell	1 (4%)	
Inflammation, Granulomatous	1 (4%)	
Axillary, Hemorrhage	- (· / • /	
Axillary, Hyperplasia, Lymphoid		
Axillary, Infiltration Cellular, Plasma Cell		
Axillary, Necrosis		1 (3%)
Cervical, Hemorrhage		,
Cervical, Hyperplasia, Lymphoid		
Cervical, Infiltration Cellular, Plasma Cell		
Deep Cervical, Necrosis		1 (3%)
Hepatic, Hyperplasia, Lymphoid		2 (6%)
Hepatic, Infiltration Cellular, Plasma Cell		
Hepatic, Inflammation, Granulomatous		1 (3%)
Hepatic, Necrosis		1 (3%)
Hepatic, Sinus, Dilatation		2 (6%)
Inguinal, Hyperplasia, Lymphoid		
Inguinal, Infiltration Cellular, Plasma Cell		1 (3%)
Inguinal, Infiltration Cellular, Polymorphonuclear		
Lumbar, Hemorrhage		
Lumbar, Hyperplasia, Lymphoid		1 (3%)
Lumbar, Infiltration Cellular, Histiocyte		
Lumbar, Infiltration Cellular, Plasma Cell	1 (4%)	2 (6%)
Lumbar, Infiltration Cellular, Polymorphonuclear		
Lumbar, Necrosis		1 (3%)
Lumbar, Pigmentation		
Lumbar, Sinus, Dilatation	3 (12%)	3 (9%)
Mediastinal, Congestion		
Mediastinal, Erythrophagocytosis		
Mediastinal, Hemorrhage		1 (3%)
Mediastinal, Hyperplasia, Lymphoid		
Mediastinal, Infiltration Cellular, Plasma Cell		
Mediastinal, Necrosis		1 (3%)
Mediastinal, Pigmentation	1 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Species/Strain: RATS/F 344/NCTR

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42

First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Madiantical Circus Diletation		4 (00()
Mediastinal, Sinus, Dilatation		1 (3%)
Pancreatic, Bacterium	4 (40()	
Pancreatic, Hemorrhage	1 (4%)	- ((()
Pancreatic, Hyperplasia, Lymphoid	6 (23%)	6 (18%)
Pancreatic, Infiltration Cellular, Histiocyte		
Pancreatic, Infiltration Cellular, Plasma Cell	4 (15%)	6 (18%)
Pancreatic, Inflammation, Granulomatous		
Pancreatic, Necrosis		1 (3%)
Pancreatic, Pigmentation		
Pancreatic, Sinus, Dilatation		4 (12%)
Popliteal, Infiltration Cellular, Plasma Cell		1 (3%)
Popliteal, Sinus, Dilatation		1 (3%)
Renal, Hemorrhage		
Renal, Hyperplasia, Lymphoid		3 (9%)
Renal, Infiltration Cellular, Plasma Cell		4 (12%)
Renal, Inflammation, Granulomatous		
Renal, Necrosis		1 (3%)
Renal, Pigmentation		
Renal, Sinus, Dilatation	2 (8%)	6 (18%)
Lymph Node, Mandibular	(50)	(50)
Hemorrhage	• •	. ,
Hyperplasia, Lymphoid	15 (30%)	13 (26%)
Infiltration Cellular, Plasma Cell	18 (36%)	22 (44%)
Necrosis	1 (2%)	1 (2%)
Pigmentation	()	()
Sinus, Dilatation	16 (32%)	15 (30%)
Lymph Node, Mesenteric	(50)	(50)
Hemorrhage	(30)	(30)
Hyperplasia, Lymphoid	15 (30%)	6 (12%)
Infiltration Cellular, Histiocyte	13 (30 /0)	0 (12/0)
Infiltration Cellular, Mast Cell		
Infiltration Cellular, Plasma Cell	3 (6%)	3 (6%)
	3 (0%)	
Inflammation, Granulomatous		1 (2%)
Pigmentation	4 (00()	4 (00/)
Sinus, Dilatation	1 (2%)	1 (2%)
Spleen	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Accessory Spleen		
Atrophy		
Cyst		
Developmental Malformation		
Fibrosis	2 (4%)	2 (4%)
Hematopoietic Cell Proliferation	13 (26%)	22 (44%)
Hemorrhage	1 (2%)	1 (2%)
Hyperplasia, Lymphoid	(=73)	(= / - /
Hyperplasia, Stromal		
Necrosis	2 (4%)	1 (2%)
Pigmentation	14 (28%)	12 (24%)
Thrombosis	(2070)	1 (2%)
Capsule, Fibrosis	1 (2%)	1 (2%)
Thymus	(50)	(49)
Atrophy	43 (86%)	42 (86%)
Cyst	10 (0070)	1 (2%)
Hemorrhage		1 (270)
Hyperplasia, Lymphoid	1 (2%)	
Necrosis	2 (4%)	1 (2%)
Adventitia, Foreign Body	2 (470)	1 (270)
Adventitia, Infiltration Cellular, Polymorphonuclear	1 (2%)	
Epithelium, Hyperplasia	1 (2%)	
INTEGUMENTARY SYSTEM		
Mammary Gland	(48)	(50)
Abscess	(40)	(30)
Fibrosis		
Galactocele	18 (38%)	24 (48%)
Hemorrhage	10 (30%)	24 (40 %)
Inflammation, Granulomatous		
Inflammation, Chronic		
Inflammation, Chronic Active		
Pigmentation		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Alveolus, Dilatation	12 (25%)	15 (30%)
Epithelium, Hyperplasia	1 (2%)	10 (0070)
Lobular, Hyperplasia	1 (2%)	4 (8%)
Skin	(50)	(50)
Abscess	()	()
Cyst Epithelial Inclusion	1 (2%)	6 (12%)
Fibrosis	1 (2%)	· (· = / · ·)
Foreign Body	(=,-,	
Hyperkeratosis		1 (2%)
Inflammation, Granulomatous		. (= /3)
Inflammation, Chronic Active	1 (2%)	
Metaplasia, Osseous	. (=/3)	1 (2%)
Ulcer	1 (2%)	. (270)
Ear, Fibrosis	. (270)	
Ear, Epithelium, Hyperplasia		
Ear, Sebaceous Gland, Hyperplasia		
Epithelium, Hyperplasia		1 (2%)
Tail, Cyst Epithelial Inclusion		1 (270)
MUSCULOSKELETAL SYSTEM		
Bone	(0)	(0)
Rib, Cyst	(-)	\~/
Tibia, Deformity		
Bone, Femur	(50)	(50)
Fibrosis	,	, ,
Fibrous Osteodystrophy	1 (2%)	3 (6%)
Osteopetrosis	, ,	, ,
Skeletal Muscle	(2)	(0)
Fibrosis	()	` '
Necrosis		
Diaphragm, Hemorrhage	1 (50%)	
Diaphragm, Infiltration Cellular, Polymorphonuclear	1 (50%)	
Diaphragm, Necrosis	1 (50%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
NERVOUS SYSTEM		
Brain	(1)	(0)
Meninges, Mineralization	1 (100%)	` ,
Brain, Brain Stem	(50)	(50)
Compression	13 (26%)	23 (46%)
Hemorrhage	,	2 (4%)
Necrosis		, ,
Brain, Cerebellum	(50)	(50)
Gliosis	, ,	
Hemorrhage		1 (2%)
Metaplasia, Osseous		•
Mineralization		
Necrosis		
Ventricle, Dilatation		
Brain, Cerebrum	(50)	(50)
Compression	1 (2%)	
Cyst		
Gliosis		
Hemorrhage		3 (6%)
Mineralization	1 (2%)	
Necrosis		
Ventricle, Dilatation	2 (4%)	3 (6%)
Peripheral Nerve	(0)	(0)
Spinal Cord, Cervical	(0)	(0)
Hemorrhage		
Axon, Degeneration		
Spinal Cord, Lumbar	(0)	(0)
Axon, Degeneration		
Spinal Cord, Thoracic	(0)	(0)
Hemorrhage		
Axon, Degeneration		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Route: GAVAGE Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
RESPIRATORY SYSTEM		
Lung	(50)	(50)
Bacterium	. ,	. ,
Congestion	1 (2%)	2 (4%)
Crystals		
Fibrosis		
Hemorrhage	4 (8%)	1 (2%)
Histiocytosis	1 (2%)	
Infiltration Cellular, Histiocyte	15 (30%)	17 (34%)
Inflammation, Suppurative		
Inflammation, Chronic	1 (2%)	1 (2%)
Inflammation, Chronic Active	1 (2%)	
Metaplasia, Osseous		
Mineralization	1 (2%)	
Necrosis	1 (2%)	
Pigmentation		
Polyarteritis		
Thrombosis		
Alveolar Epithelium, Hyperplasia	2 (4%)	3 (6%)
Bronchiole, Epithelium, Hyperplasia		
Mediastinum, Fibrosis		
Mediastinum, Hemorrhage	1 (2%)	
Mediastinum, Inflammation, Suppurative	1 (2%)	
Mediastinum, Inflammation, Chronic Active		
Mediastinum, Necrosis	1 (2%)	
Pleura, Bacterium		
Pleura, Foreign Body		
Pleura, Hemorrhage		
Pleura, Infiltration Cellular, Polymorphonuclear		
Pleura, Inflammation, Suppurative		
Pleura, Inflammation, Chronic		
Pleura, Necrosis		
Nose	(50)	(48)
Cyst	1 (2%)	
Foreign Body	6 (12%)	7 (15%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

0.92 Furan 104wk	2 Furan 104 wk
9 (18%)	9 (19%)
, ,	, ,
(50)	(50)
(0)	(0)
	(47)
	6 (13%)
,	1 (2%)
	, ,
	1 (2%)
3 (6%)	6 (13%)
	(50)
3 (6%)	1 (2%)
, ,	, ,
	1 (2%)
	(-/-/
(1)	(1)
` '	()
1 (100%)	
	9 (18%) (50) (0) (50) 1 (2%) 3 (6%) (50) 3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 Time Report Requested: 08:42:42 First Dose M/F: 09/07/09 / NA

FISCHER 344 RATS-NCTR RATS MALE	0.92 Furan 104wk	2 Furan 104 wk
Keratin Cyst		1 (100%)
URINARY SYSTEM		
Kidney	(50)	(50)
Casts Protein		
Cyst	2 (4%)	3 (6%)
Hydronephrosis	7 (14%)	7 (14%)
Infarct		
Inflammation, Suppurative		
Mineralization		1 (2%)
Necrosis	1 (2%)	
Nephropathy	49 (98%)	49 (98%)
Pigmentation		
Polyarteritis		
Polycystic Kidney		
Thrombosis	1 (2%)	
Capsule, Fibrosis		
Pelvis, Inflammation, Suppurative		1 (2%)
Renal Tubule, Degeneration		
Renal Tubule, Dilatation		
Transitional Epithelium, Hyperplasia	12 (24%)	19 (38%)
Urethra	(0)	(0)
Bulbourethral Gland, Inflammation, Suppurative)	
Lumen, Dilatation		
Urinary Bladder	(50)	(50)
Hemorrhage		
Inflammation, Suppurative		
Inflammation, Chronic		
Inflammation, Chronic Active	1 (2%)	
Lumen, Dilatation	1 (2%)	3 (6%)
Serosa, Inflammation, Chronic Active		
Transitional Epithelium, Hyperplasia	2 (4%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

Species/Strain: RATS/F 344/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Furan

CAS Number: 110-00-9

Date Report Requested: 06/03/2014 **Time Report Requested:** 08:42:42

First Dose M/F: 09/07/09 / NA

Lab: NCTR

FISCHER 344 RATS-NCTR RATS MALE

0.92 Furan 104wk

2 Furan 104 wk

*** END OF REPORT ***